Biomedical Engineering Reference
In-Depth Information
132. Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, Li T, Liu J, Yang TL,
Wang D, Zhong XY, Zhou HH. 2004. St. John's wort induces both cytochrome P450
3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin
Pharmacol Ther 75: 191-197.
133. Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernas H. 2004.
St. John's wort decreases the bioavailability of R- and S-verapamil through induction of
the first-pass metabolism. Clin Pharmacol Ther 75: 298-309.
134. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. 2004. Effect of St. John's
wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 76: 323-329.
135. Bauer S, Stormer E, Johne A, Kruger H, Budde K, Neumayer HH, Roots I, Mai I. 2003.
Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with
St. John's wort in renal transplant patients. Br J Clin Pharmacol 55: 203-211.
136. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller
M, Gorski JC. 2003. The interaction between St. John's wort and an oral contraceptive.
Clin Pharmacol Ther 74: 525-535.
137. Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK,
Sawyer WH. 1992. Reversal of multidrug resistance by surfactants. Br J Cancer 66: 62-68.
138. Martin-Facklam M, Burhenne J, Ding R, Fricker R, Mikus G, Walter-Sack I, Haefeli
WE. 2002. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic
aid cremophor EL. Br J Clin Pharmacol 53: 576-581.
139. Tayrouz Y, Ding R, Burhenne J, Riedel KD, Weiss J, Hoppe-Tichy T, Haefeli WE, Mikus
G. 2003. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor
RH40. Clin Pharmacol Ther 73: 397-405.
140. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB.
2002. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake
to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71: 11-20.
141. Spahn-Langguth H, Langguth P. 2001. Grapefruit juice enhances intestinal absorption of
the P-glycoprotein substrate talinolol. Eur J Pharm Sci 12: 361-367.
142. Schwarz UI, Seemann D, Oertel R, Miehlke S, Kuhlisch E, Fromm MF, Kim RB, Bailey
DG, Kirch W. 2005. Grapefruit juice ingestion significantly reduces talinolol bioavail-
ability. Clin Pharmacol Ther 77: 291-301.
143. Wang EJ, Casciano CN, Clement RP, Johnson WW. 2001. Inhibition of P-glycoprotein
transport function by grapefruit juice psoralen. Pharm Res 18: 432-438.
144. Takanaga H, Ohnishi A, Matsuo H, Sawada Y. 1998. Inhibition of vinblastin efflux medi-
ated by P-glycoprotein by grapefruit juice components in Caco-2 cells. Biol Pharm Bull
21: 1062-1066.
145. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, Funck-Brentano C.
2001. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol
Ther 70: 311-316.
146. Rogan AM, Hamilton TC, Young RC, Klecker RW Jr, Ozols RF. 1984. Reversal of
adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994-996.
147. Fisher GA, Sikic BI. 1995. Clinical studies with modulators of multidrug resistance.
Hematol Oncol Clin North Am 9: 363-382.
148. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M,
Dalton W. 1993. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier
in acute leukemia. J Clin Oncol 11: 1652-1660.
Search WWH ::
Custom Search